D
David Rubanowice
Researcher at Group Health Cooperative
Publications - 5
Citations - 667
David Rubanowice is an academic researcher from Group Health Cooperative. The author has contributed to research in topics: Poison control & Randomized controlled trial. The author has an hindex of 5, co-authored 5 publications receiving 644 citations.
Papers
More filters
Journal ArticleDOI
Medical care utilization patterns in women with diagnosed domestic violence.
Yvonne Ulrich,Kevin C. Cain,Nancy K. Sugg,Frederick P. Rivara,David Rubanowice,Robert S. Thompson +5 more
TL;DR: It is concluded that being a DV case-patient is associated with between 1.6- and 2.3-fold increases in total utilization and costs.
Journal ArticleDOI
Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy.
Robert L. Davis,David Rubanowice,Heather McPhillips,Marsha A. Raebel,Susan E. Andrade,David H. Smith,Marianne Ulcickas Yood,Richard Platt,Richard Platt +8 more
TL;DR: To evaluate risks for perinatal complications and congenital defects among infants exposed in utero to antidepressants, a large number of patients were exposed to antidepressants in the first trimester of pregnancy.
Journal ArticleDOI
Identification and management of domestic violence: a randomized trial.
Robert S. Thompson,Frederick P. Rivara,Diane C. Thompson,William E. Barlow,Nancy K. Sugg,Roland D Maiuro,David Rubanowice +6 more
TL;DR: The intervention improved documented asking about DV in practice up to 9 months later and system changes appear to be a cost-effective method to increase DV asking and identification.
Journal ArticleDOI
Patient use of secure electronic messaging within a shared medical record: a cross-sectional study.
James D. Ralston,Carolyn M. Rutter,David Carrell,Julia Hecht,David Rubanowice,Gregory E. Simon +5 more
TL;DR: In this integrated group practice, use of patient–provider secure messaging varied according to individual patient clinical and sociodemographic characteristics.
Journal ArticleDOI
Diphtheria Antitoxin Levels among Children Primed with a Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Lot with a Subpotent Diphtheria Toxoid Component
Lisa A. Jackson,Lisa A. Jackson,Sherry Falls,Onchee Yu,Jim George,Patricia J Pietrobon,David Rubanowice,James E. Froeschle +7 more
TL;DR: The booster response to dose 4, although reduced, was sufficient to confer adequate protection in the interval before receipt of the fifth dose of DTaP, indicating that diphtheria potency testing can identify vaccine that is less immunogenic when administered during the primary series.